EU clears Baxter's $2.76 billion takeover of Swedish dialysis firm Gambro, with conditions

  • Updated: July 22, 2013 - 11:25 AM

BERLIN — The European Union's antitrust authority has cleared U.S. pharmaceutical company Baxter's proposed $2.76 billion takeover bid of Sweden's dialysis products firm Gambro.

The European Commission said Monday the acquisition can go ahead on condition that Baxter divest its renal replacement therapy, which serves patients suffering from acute kidney failure.

The Commission, the 28-nation bloc's antitrust watchdog, said Baxter's commitment to selling that business line has appeased concerns the takeover would stifle competition in the segment.

Gambro AB makes dialysis products for patients with acute or chronic kidney disease and it has annual sales of about $1.6 billion.

Baxter International Inc., based in Deerfield, Illinois, proposed to buy the privately held Swedish firm in December.

  • get related content delivered to your inbox

  • manage my email subscriptions

ADVERTISEMENT

Connect with twitterConnect with facebookConnect with Google+Connect with PinterestConnect with PinterestConnect with RssfeedConnect with email newsletters

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

 
Close